INVESTIGATING SECONDARY EFFECTS OF BACE1 INHIBITION, A PROMISING THERAPY FOR ALZHEIMER'S DISEASE

Abstract

Synapses transfer information between neurons in the brain. In Alzheimer’s disease (AD), synapse loss results in dementia therefore it is imperative that any potential therapeutic drugs do not inadvertently cause further synapse loss. Drugs aimed at blocking production of toxic protein fragments in AD might have adverse secondary effects on synapse development and function. This research will determine whether this is the case and inform new therapeutic approaches aimed at minimizing side effects.

Related publications (1)

BACE Inhibition as a Therapeutic Strategy for Alzheimer’s Disease

G Evin, SJ Fuller, JM Gunnersen

2015-07-22

Alzheimer’s disease (AD) is the most common age-related neurodegenerative disease and the most common cause of dementia. One of th..